マーケットレポート詳細
マイクロバイオーム診断市場：技術別、サンプル別2028年予測
Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
- 出版元：MarketsandMarkets
出版元について - 発行年：2024年2月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文179ページになります。
- 商品コード：MAM3551
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
マイクロバイオーム診断の世界市場規模は2023年で1億4600万ドル、2028年に３億ドル、市場の平均年成長率は15.5%にて増加すると見込まれています。
レポートはマイクロバイオーム診断の世界市場について2028年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（製品別市場、技術別市場、等）を中心に構成されています。また競合状況、主要企業情報（15社）、サプライチェーン分析、ファイブフォース分析なども加味し、マイクロバイオーム診断市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆マイクロバイオーム診断市場の世界市場予測2021-2028年
・市場規模(US$)
◆製品別、市場-2028年
・キット、試薬
・計測器
※(市場規模US$)
◆技術別、市場-2028年
・16S rRNA解析
・ショットガンメタゲノムシーケンス
・メタトランスクリプトミクス
・その他技術
※(市場規模US$)
◆サンプル別、市場-2028年
・糞便サンプル
・唾液サンプル
・皮膚サンプル
・その他サンプル
※(市場規模US$)
◆用途別、市場-2028年
疾患診断アプリケーション
・胃腸疾患
・代謝性疾患
・その他疾患診断アプリケーション
研究用途
※(市場規模US$)
◆エンドユーザー別、市場-2028年
・病院
・研究機関
・製薬、バイオテクノロジー企業
※(市場規模US$)
◆主要国地域別市場-2028年
北米
・米国、カナダ
欧州
・ドイツ、フランス、英国
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
その他地域
※地域別、国別に全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス
・バリューチェーン分析
・サプライチェーン分析
・ファイブフォース分析
・主要なステークホルダーと購買基準
・規制状況
・エコシステム分析
・特許分析
・平均価格分析
・技術分析
・貿易分析
・競合状況
・市場シェア分析
◆マイクロバイオーム診断市場の主要企業プロフィール動向
・GENETIC ANALYSIS AS
・DNA GENOTEK (ORASURE TECHNOLOGIES, INC)
・MICROBA LIFE SCIENCES
・ILLUMINA INC
・OXFORD NANOPORE TECHNOLOGIES, PLC
・BIOME OXFORD LTD
・VIENNALAB DIAGNOSTICS GMBH
・METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC)
・VIOME LIFE SCIENCES
・LUXIA SCIENTIFIC
・SUN GENOMICS
・ATLAS BIOMED
・QUANTBIOME, INC (DBA OMBRE)
・BECTON, DICKINSON AND COMPANY
・DAYTWO
その他企業
・MICRONOMA
・TERAOMICS SL
・FLIGHTPATH BIOSCIENCES
・MICROBIOME RESEARCH PVT LTD
・ORIGIN SCIENCES
・LEUCINE RICH BIO PRIVATE LIMITED
・DECODE AGE
・EVVY
・ALPHABIOMICS, LTD
・GOODGUT
（全179頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
・ TABLE 1 INCLUSIONS & EXCLUSIONS 27
1.3 STUDY SCOPE 27
・ FIGURE 1 MICROBIOME-BASED DIAGNOSTICS MARKET SCOPE
1.3.1 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
・ FIGURE 2 MICROBIOME-BASED DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY DATA
・ FIGURE 3 PRIMARY SOURCES
2.1.2.1 KEY DATA FROM PRIMARY SOURCES
2.1.2.2 KEY INDUSTRY INSIGHTS
・ FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
2.1.2.3 BREAKDOWN OF PRIMARY INTERVIEWS
・ FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
・ FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.2.1.2 APPROACH 2: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
2.2.1.3 APPROACH 3: PRIMARY RESEARCH
2.2.1.4 GROWTH FORECAST
2.2.1.5 CAGR PROJECTIONS
・ FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH 37
・ FIGURE 8 MICROBIOME-BASED DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
・ FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 STUDY ASSUMPTIONS
2.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT
・ TABLE 2 RISK ASSESSMENT: MICROBIOME-BASED DIAGNOSTICS MARKET
2.6 IMPACT OF RECESSION ON MICROBIOME-BASED DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
・ FIGURE 10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
・ FIGURE 11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
・ FIGURE 12 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2023 VS. 2028 (USD MILLION)
・ FIGURE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
・ FIGURE 14 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
・ FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MICROBIOME-BASED DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 MICROBIOME-BASED DIAGNOSTICS MARKET OVERVIEW
・ FIGURE 16 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022)
・ FIGURE 17 KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT
・ FIGURE 18 CHINA AND INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
4.4 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHIC MIX
・ FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 MICROBIOME-BASED DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES
・ FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 21 MICROBIOME-BASED DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 GROWING PREVALENCE OF CHRONIC DISEASES
・ FIGURE 22 GLOBAL INCIDENCE OF DIABETES, 2021 VS. 2045
5.2.1.2 COLLABORATIVE EFFORTS BETWEEN MICROBIOME INDUSTRY AND ACADEMIA FOR MICROBIOME RESEARCH
5.2.1.3 GROWING DEMAND FOR PERSONALIZED MEDICINE
5.2.1.4 RISING AWARENESS ABOUT IMPORTANCE OF HUMAN MICROBIOMES
5.2.1.5 RISING FUNDING AND INVESTMENTS IN MICROBIOME RESEARCH
5.2.2 RESTRAINTS
5.2.2.1 END-USER BUDGET CONSTRAINTS IN DEVELOPING COUNTRIES
5.2.3 OPPORTUNITIES
5.2.3.1 INCREASED COLLABORATION BETWEEN KEY PLAYERS AND SMALL INNOVATIVE COMPANIES TO WORK ON NEW MICROBIOME TECHNOLOGIES
・ TABLE 3 COLLABORATIONS IN MICROBIOME-BASED DIAGNOSTICS MARKET
5.2.4 CHALLENGES
5.2.4.1 ADVERSE IMPACT OF COMPLEX REGULATORY POLICIES ON COMMERCIALIZATION OF MICROBIOME
5.3 VALUE CHAIN ANALYSIS
・ FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.4 SUPPLY CHAIN ANALYSIS
・ FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 INTENSITY OF COMPETITIVE RIVALRY
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 THREAT OF SUBSTITUTES
5.6 KEY STAKEHOLDERS & BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
・ FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 2 END USERS
5.6.2 BUYING CRITERIA 60
・ FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS
5.7 REGULATORY LANDSCAPE
5.7.1 NORTH AMERICA
・ TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2 EUROPE
・ TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.3 ASIA PACIFIC
・ TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.4 REST OF THE WORLD 63
・ TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 ECOSYSTEM ANALYSIS
・ TABLE 8 ROLE IN ECOSYSTEM
・ FIGURE 27 KEY PLAYERS OPERATING IN MICROBIOME-BASED DIAGNOSTICS MARKET
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES & EVENTS
・ TABLE 9 LIST OF CONFERENCES & EVENTS IN 2023–2024
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
・ TABLE 10 PRICE RANGE OF PRODUCTS OFFERED BY KEY PLAYERS FOR APPLICATIONS (USD)
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13 TECHNOLOGY ANALYSIS
5.13.1 DEVELOPMENT OF NOVEL MICROBIOME SAMPLING DEVICES
5.14 TRADE ANALYSIS
・ TABLE 11 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
・ TABLE 12 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
6 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
・ TABLE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 KITS & REAGENTS
6.2.1 KITS & REAGENTS TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
・ TABLE 14 MICROBIOME-BASED DIAGNOSTIC KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS 71
6.3.1 INCREASING VOLUME OF BLOOD COLLECTION PROCEDURES TO DRIVE MARKET GROWTH
・ TABLE 15 MICROBIOME-BASED DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
7 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
・ TABLE 16 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 16S RRNA SEQUENCING
7.2.1 ABILITY TO COMBINE MANY SAMPLES IN SEQUENCING RUN TO DRIVE DEMAND FOR NGS-BASED 16S RRNA SEQUENCING
・ TABLE 17 MICROBIOME-BASED DIAGNOSTICS MARKET FOR 16S RRNA SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
7.3 SHOTGUN METAGENOMICS
7.3.1 ABILITY OF SHOTGUN METAGENOMICS TO PROVIDE DETAILED GENETIC INFORMATION TO BOOST DEMAND
・ TABLE 18 COMPARISON BETWEEN SHOTGUN METAGENOMICS AND 16S RRNA SEQUENCING
・ TABLE 19 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SHOTGUN METAGENOMICS, BY REGION, 2021–2028 (USD MILLION)
7.4 METATRANSCRIPTOMICS
7.4.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING INSTRUMENTS TO DRIVE GROWTH
・ TABLE 20 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METATRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION) 77
7.5 OTHER TECHNOLOGIES
・ TABLE 21 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE
8.1 INTRODUCTION
・ TABLE 22 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
8.2 FECAL SAMPLES
8.2.1 FECAL SAMPLES TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
・ TABLE 23 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR FECAL SAMPLES
・ TABLE 24 MICROBIOME-BASED DIAGNOSTICS MARKET FOR FECAL SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.3 SALIVA SAMPLES
8.3.1 ADVANCEMENTS IN ORAL DIAGNOSTICS TO DRIVE MARKET GROWTH
・ TABLE 25 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SALIVA SAMPLES
・ TABLE 26 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SALIVA SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.4 SKIN SAMPLES
8.4.1 GROWING FOCUS ON MICROBIOME RESEARCH ACTIVITIES TO BOOST MARKET
・ TABLE 27 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SKIN SAMPLES
・ TABLE 28 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SKIN SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER SAMPLES
・ TABLE 29 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR OTHER SAMPLES
・ TABLE 30 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION)
9 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
・ TABLE 31 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 DISEASE DIAGNOSTIC APPLICATIONS
・ TABLE 32 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 33 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9.2.1 GASTROINTESTINAL DISORDERS
9.2.1.1 GROWING INCIDENCE OF GASTROINTESTINAL DISORDERS TO DRIVE MARKET GROWTH
・ TABLE 34 MICROBIOME-BASED DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.2.2 METABOLIC DISORDERS
9.2.2.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE DEMAND FOR MICROBIOME-BASED DIAGNOSTIC PRODUCTS
・ TABLE 35 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.2.3 OTHER DISEASE DIAGNOSTIC APPLICATIONS
・ TABLE 36 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9.3 RESEARCH APPLICATIONS
9.3.1 GROWING RESEARCH ACTIVITIES TO BOOST MARKET
・ TABLE 37 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
・ TABLE 38 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 HOSPITALS 90
10.2.1 HOSPITALS ACCOUNTED FOR LARGEST SHARE OF MICROBIOME-BASED DIAGNOSTICS MARKET IN 2022
・ TABLE 39 MICROBIOME-BASED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
10.3 RESEARCH INSTITUTES
10.3.1 GROWING FUNDING FOR MICROBIOME RESEARCH TO SUPPORT MARKET GROWTH
・ TABLE 40 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.4.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE DEMAND FOR MICROBIOME-BASED PRODUCTS
・ TABLE 41 MICROBIOME-BASED DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
・ TABLE 42 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
・ FIGURE 28 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
・ TABLE 43 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 44 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 45 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 46 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 47 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 48 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 49 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 US TO ACCOUNT FOR LARGEST SHARE OF DURING FORECAST PERIOD
・ TABLE 50 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 51 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 52 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 53 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 54 US: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 55 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 HIGH PREVALENCE OF DISEASES IN CANADA TO SUPPORT MARKET GROWTH
・ TABLE 56 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 57 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 58 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 59 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 60 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 61 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
・ TABLE 62 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 63 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 64 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 65 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 66 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 67 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 68 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 GERMANY TO DOMINATE EUROPEAN MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
・ TABLE 69 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 70 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 71 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 72 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 73 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 74 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 GROWING NUMBER OF MICROBIOME SEQUENCING START-UPS TO BOOST MARKET GROWTH
・ TABLE 75 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 76 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 77 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 78 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 79 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 80 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 UK
11.3.3.1 SUPPORTIVE ENVIRONMENT FOR MICROBIOME SEQUENCING R&D TO SUPPORT GROWTH
・ TABLE 81 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 82 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 83 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 84 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 85 UK: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 86 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 REST OF EUROPE
・ TABLE 87 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 88 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 89 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 90 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 91 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 92 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
・ FIGURE 29 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
・ TABLE 93 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 94 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 95 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 96 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 97 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 98 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 99 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 COLLABORATIONS BETWEEN ACADEMIC INSTITUTES AND PRIVATE COMPANIES TO DRIVE GROWTH
・ TABLE 100 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 101 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 102 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 103 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 104 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 105 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 RISING AGING POPULATION TO DRIVE MARKET GROWTH
・ TABLE 106 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 107 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 108 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 109 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 110 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 111 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 INCREASING PREVALENCE OF DISEASES TO DRIVE MARKET GROWTH
・ TABLE 112 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 113 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 114 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 115 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 116 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 117 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
・ TABLE 118 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 119 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 120 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 121 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 122 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 123 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 ASIA PACIFIC: RECESSION IMPACT
11.5 REST OF THE WORLD
・ TABLE 124 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
・ TABLE 125 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
・ TABLE 126 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
・ TABLE 127 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
・ TABLE 128 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 129 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 REST OF THE WORLD: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
・ TABLE 130 OVERVIEW OF STRATEGIES ADOPTED BY KEY MICROBIOME-BASED DIAGNOSTIC MANUFACTURERS
12.3 REVENUE ANALYSIS
・ FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS
12.4 MARKET SHARE ANALYSIS
・ TABLE 131 MICROBIOME-BASED DIAGNOSTICS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS 138
12.5.3 PERVASIVE PLAYERS 138
12.5.4 PARTICIPANTS
・ FIGURE 31 MICROBIOME-BASED DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
12.5.5 COMPANY FOOTPRINT ANALYSIS
・ TABLE 132 COMPANY FOOTPRINT
・ TABLE 133 COMPANY PRODUCT FOOTPRINT
・ TABLE 134 COMPANY REGIONAL FOOTPRINT 142
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES 143
12.6.4 STARTING BLOCKS 143
・ FIGURE 32 MICROBIOME-BASED DIAGNOSTICS MARKET: START-UP/SME EVALUATION MATRIX, 2022
12.6.5 COMPETITIVE BENCHMARKING
・ TABLE 135 MICROBIOME-BASED DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.7 COMPETITIVE SCENARIO & TRENDS
12.7.1 PRODUCT LAUNCHES & APPROVALS
・ TABLE 136 MICROBIOME-BASED DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2023
12.7.2 DEALS
・ TABLE 137 MICROBIOME-BASED DIAGNOSTICS MARKET: DEALS, 2020–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS 147
(BUSINESS OVERVIEW, PRODUCTS/SERVICES/SOLUTIONS OFFERED, MNM VIEW, KEY STRENGTHS AND RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESSES AND COMPETITIVE THREATS, RECENT DEVELOPMENTS)*
13.1.1 GENETIC ANALYSIS AS
・ TABLE 138 GENETIC ANALYSIS AS: COMPANY OVERVIEW
・ FIGURE 33 GENETIC ANALYSIS AS: COMPANY SNAPSHOT (2022)
13.1.2 DNA GENOTEK (ORASURE TECHNOLOGIES, INC.)
・ TABLE 139 DNA GENOTEK: COMPANY OVERVIEW
・ FIGURE 34 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
13.1.3 MICROBA LIFE SCIENCES
・ TABLE 140 MICROBA LIFE SCIENCES: COMPANY OVERVIEW
・ FIGURE 35 MICROBA LIFE SCIENCES: COMPANY SNAPSHOT (2023)
13.1.4 ILLUMINA INC.
・ TABLE 141 ILLUMINA INC.: COMPANY OVERVIEW
・ FIGURE 36 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
13.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC
・ TABLE 142 OXFORD NANOPORE TECHNOLOGIES, PLC: COMPANY OVERVIEW
・ FIGURE 37 OXFORD NANOPORE TECHNOLOGIES, PLC.: COMPANY SNAPSHOT (2022)
13.1.6 BIOME OXFORD LTD. 162
・ TABLE 143 BIOME OXFORD LTD.: COMPANY OVERVIEW
13.1.7 VIENNALAB DIAGNOSTICS GMBH
・ TABLE 144 VIENNALAB DIAGNOSTICS GMBH: COMPANY OVERVIEW
13.1.8 METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC.)
・ TABLE 145 METABIOMICS: COMPANY OVERVIEW
13.1.9 VIOME LIFE SCIENCES
・ TABLE 146 VIOME LIFE SCIENCES: COMPANY OVERVIEW
13.1.10 LUXIA SCIENTIFIC
・ TABLE 147 LUXIA SCIENTIFIC: COMPANY OVERVIEW
13.1.11 SUN GENOMICS
・ TABLE 148 SUN GENOMICS: COMPANY OVERVIEW
13.1.12 ATLAS BIOMED
・ TABLE 149 ATLAS BIOMED: COMPANY OVERVIEW
13.1.13 QUANTBIOME, INC. (DBA OMBRE) 169
・ TABLE 150 QUANTBIOME, INC.: COMPANY OVERVIEW
13.1.14 BECTON, DICKINSON AND COMPANY
・ TABLE 151 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
・ FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
13.1.15 DAYTWO
・ TABLE 152 DAYTWO: COMPANY OVERVIEW
*BUSINESS OVERVIEW, PRODUCTS/SERVICES/SOLUTIONS OFFERED, MNM VIEW, KEY STRENGTHS AND RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESSES AND COMPETITIVE THREATS, RECENT DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
13.2 OTHER PLAYERS
13.2.1 MICRONOMA
13.2.2 TERAOMICS S.L.
13.2.3 FLIGHTPATH BIOSCIENCES
13.2.4 MICROBIOME RESEARCH PVT. LTD.
13.2.5 ORIGIN SCIENCES 175
13.2.6 LEUCINE RICH BIO PRIVATE LIMITED
13.2.7 DECODE AGE
13.2.8 EVVY
13.2.9 ALPHABIOMICS, LTD.
13.2.10 GOODGUT